Atlas Trials

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Clinical trial NCT05613088 · COMPLETED

Trial details

NCT number
NCT05613088
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Neoplasms, Ovarian
Start date
2023-02-01
Primary completion
2024-06-17
Enrollment
106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.